Among the highlights of WCLC are final overall survival (OS) data from AstraZeneca's FLAURA 2 study of EGFR inhibitor Tagrisso (osimertinib) given in combination with chemotherapy as a first-line ...

This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them. In September, it was reported that the company agreed to ...